Subscribe

What are you looking for?

Main Menu

明報新聞網

亞盛醫藥：利生妥III期臨床研究獲FDA和EMA批准 股價曾升逾10% 創新高

Future Wealths
Future Wealths
18 8 月, 2025
One Min Read
6 Views
0 Comments
亞盛醫藥－Ｂ(6855)公布，亞盛醫藥利生妥®一線治療中高危MDS患者的全球註冊III期臨床研究 獲美國FDA和歐洲EMA批准。

原文: https://finance.mingpao.com/fin/instantf/20250818/1755483438075/%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5-%e5%88%a9%e7%94%9f%e5%a6%a5iii%e6%9c%9f%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6%e7%8d%b2fda%e5%92%8cema%e6%89%b9%e5%87%86-%e8%82%a1%e5%83%b9%e6%9b%be%e5%8d%87%e9%80%be10-%e5%89%b5%e6%96%b0%e9%ab%98

Last Update: 18 8 月, 2025

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept